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nomical standpoint, the total avoidable cost with TPN mounted to 2,48,200 Indian 
Rupees. ConClusions: Proper use of TPN reduced mortality in post-surgical 
patients. Greater attention to nutritional assessment to determine calorific need 
and nutritional requirement for individual patients should further improve benefits, 
reduce mortality and save treatment costs in hospitalized patients.
PGI44
A HeAltH tecHnoloGy-RelAted cost descRIPtIon conceRnInG ItAlIAn 
Ibd centRes deAlInG WItH cRoHn’s dIseAse: Results FRom sole study
Lazzaro C.1, Cappello M.2, Cortelezzi C.3, Costantino G.4, Fiorino G.5, Mastronardi M.6, 
Giannotta M.7, Galletti B.8, Cicala M.9, Vadalà di Prampero S.10, Gualberti G.11, Caprioli F.12, 
Gasbarrini A.13, Fattore G.14
1Studio di Economia Sanitaria, Milan, Italy, 2Università di Palermo, Palermo, Italy, 3AOU di 
Circolo - Fondazione Macchi, Varese, Italy, 4Università di Messina, Messina, Italy, 5Istituto Clinico 
Humanitas, Rozzano (MI), Italy, 6IRCCS S. De Bellis, Castellana Grotte, Italy, 7Azienda Ospedaliero 
Universitaria di Careggi, Firenze, Italy, 8Ospedale S. Salvatore, L’Aquila, Italy, 9Università Campus 
Bio Medico, Roma, Italy, 10Azienda Ospedaliero-Universitaria S. Maria della Misericordia di 
Udine, Udine, Italy, 11AbbVie, Campoverde di Aprilia (LT), Italy, 12Università degli Studi di Milano, 
Milano, Italy, 13Università Cattolica del Sacro Cuore, Rome, Italy, 14Bocconi University, Milan, Italy
objeCtives: To investigate the health technology-related costs of Italian inflam-
matory bowel disease (IBD) centers dealing with Crohn’s disease (CD). Methods: 
Following the hospital standpoint, a questionnaire-supported cost description 
was performed on a convenience sample of 38 Italian IBD centers participating 
in the ongoing Survey on Quality Of Life in Crohn’s Patients (SOLE). Consistently with 
their average useful life, a 5-year straight-line depreciation approach was adopted 
for calculating the yearly cost for each health technology. Cost description was 
undertaken either considering all centers as an undifferentiated sample, or strati-
fying them according to their complexity (number of beds for inward and day-
hospital; personnel dedicated to CD patients; number of cross-border CD patients; 
availability of dedicated rooms for biological drugs administration; feasibility of 
electronic patient forms). Costs (€ 2012) were reported as mean (standard devia-
tion, SD). Results: Half of centers (19/38) were public teaching hospitals, whereas 
39.5% were regional referral centers for CD (15/38). The study sites were located in 
Northern (12/38, 31.6%), Central (11/38, 28.9%) and Southern (15/38, 39.5%) Italy, and 
could be classified as high (32/38, 84.2%), moderate (1/38), mild (3/38), and low (2/38) 
complexity centers. Endoscopy, capsule endoscopy and ultrasonography were the 
most widespread health technologies available in 92.1%, 78.9% and 34.2% centers, 
respectively. Considering the undifferentiated sample, mean yearly cost for health 
technologies amounts to € 23,557.50 (€ 24,277.90). High complexity centers report the 
highest mean yearly cost of € 25,580.38 (€ 25,706.92), whereas the lowest mean yearly 
cost of € 5,113 (€ 0) refers to the unique moderate complexity center. Regardless of 
site complexity, the cost-driver was endoscopy, which accounts for a percentage 
of the mean yearly cost that ranges from 36.9% (high complexity) to 97.8% (moder-
ate complexity). ConClusions: SOLE results show that when Italian IBD centers 
complexity is taken into account, remarkable differences exist about costs for health 
technologies for managing CD patients.
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objeCtives: The IBIS-C study assessed the burden of IBS-C in 6 European countries 
(France, Germany, Italy, Spain, Sweden, and UK). Here we present the diagnosis and 
management results for the Spanish cohort. Methods: Observational, retrospec-
tive-prospective (6 months each) study in patients diagnosed with moderate-to-
severe IBS-C in the last five years (Rome-III criteria). Moderate-to-severe IBS-C was 
defined as an IBS-Symptom Severity Score (IBS-SSS) ≥ 175. Results: 112 patients 
were included (58% severe, mean age [±SD] 46.8 ± 13.7 years, 86% female). Mean time 
since diagnosis: 2.3 ± 2.7 years; mean symptom duration: 9.6 ± 9.9 years. Diagnostic 
procedures were highly variable; the most common were blood tests (71%), colo-
noscopy (56%) and abdominal ultrasound (54%). At inclusion the most prevalent 
symptoms were constipation (84%), abdominal pain (80%), abdominal distention 
(80%) and bloating (59%). Main ongoing comorbidities were dyspepsia (41%), anxiety 
(38%), depression (21%), headache (25%), or insomnia (25%). 58% of patients had an 
average of 4.1 ± 2.5 diagnostic tests during follow-up. 85% of patients took pharma-
cological medication (80% took some pharmacological medication for their IBS-C). 
The most common prescription drugs were plantago ovata (35%), otilonium bromide 
(22%), macrogol plus electrolites (13%) and cinitapride tartrate (10%). Likewise, com-
mon drug combinations were laxative monotherapy (21%), laxatives and antispas-
modics (14%), and antispasmodic monotherapy (5%). In addition, 30% of patients 
received complementary therapies. Overall, marginal improvement was noted in 
symptom severity (IBS-SSS total score) between baseline (315±83) and the 6-month 
visit (234±98). ConClusions: Moderate-to-severe IBS-C symptoms often remain 
undiagnosed for many years. With frequent visits to health care professionals IBS-C 
continues to be a burden despite the availability of therapeutic interventions. Finally, 
current health care resource utilization is high even though there is a high degree 
of prescription medication use.
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objeCtives: While discussions on health technology assessment (HTA) in Japan 
continue, platforms for real-world population-based studies are lacking. We attempt 
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objeCtives: There has been a debate on whether cost-effectiveness analysis 
should consider the cost of consumption and leisure time activities when using 
the quality-adjusted life year as a measure of health outcome under a societal 
perspective. The purpose of this study was to investigate whether the effects of ill 
health on consumptive activities are spontaneously considered in a health state 
valuation exercise and how much this matters. Methods: The survey enrolled 
patients with inflammatory bowel disease in Germany (n = 104). Patients were 
randomized to explicit and no explicit instruction for the consideration of con-
sumption and leisure effects in a time trade-off (TTO) exercise. Results: Explicit 
instruction to consider non-health-related utility in TTO exercises did not influence 
TTO scores. However, spontaneous consideration of non-health-related utility in 
patients without explicit instruction (60% of respondents) led to significantly lower 
TTO scores. ConClusions: Results suggest an inclusion of consumption costs 
in the numerator of the cost-effectiveness ratio, at least for those respondents 
who spontaneously consider non-health-related utility from treatment. Given the 
importance of this question for the conduct of cost-effectiveness analysis in health 
care, confirmation in additional studies that are conducted outside Germany and 
consider other health-state valuation techniques and diseases is recommended.
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objeCtives: To assess work productivity and daily activity impairment among 
irritable bowel syndrome with constipation (IBS-C) patients in the United 
States. Methods: IBS-C patients aged ≥ 18 years with continuous medical and 
pharmacy benefit eligibility (03/01/2011–02/28/2013) were identified from claims 
in the HealthCore Integrated Research Database and invited to complete a cross-
sectional patient survey. Survey questions based on modified Rome III criteria 
confirmed IBS-C claims-based diagnoses. Patients who met both claims-based 
and Rome criteria completed the full survey, including the Work Productivity and 
Activity Impairment Questionnaire: General Health (WPAI: GH), which assessed the 
impact of general health problems on patients’ ability to work and function. WPAI: 
GH scores for absenteeism (work hours missed), presenteeism (lost productivity at 
work), and overall work productivity loss (absenteeism + presenteeism) over the 
previous week were calculated for employed respondents; daily activity impairment 
(functional impairment) was computed for all respondents. Follow-up questions 
adapted from the WPAI: GH evaluated work and activity impairment due to IBS-C. 
Scores are expressed as percentages, with higher percentages indicating greater 
impairment and less productivity. Indirect costs were calculated based on overall 
work productivity loss due to IBS-C using the human capital method. Results: 
Of 53 respondents (mean age: 40±15 years; 84.9% female), 35 were employed. 
Absenteeism averaged 10.6%, presenteeism averaged 37.4%, overall work produc-
tivity loss averaged 39.3%, and daily activity impairment averaged 45.7% due to 
general health problems over the past week. Of this, 7.5%, 21.5%, 23.8%, and 14.2% 
was attributed to IBS-C, respectively. The economic cost due to lost productiv-
ity attributable to IBS-C was estimated at $155±$321 USD per employed patient/
week. ConClusions: IBS-C–related impairment at work and in daily activities 
represents a significant burden for patients and employers. Treatments that effec-
tively manage IBS-C symptoms may represent cost savings in the form of avoided 
work productivity losses associated with IBS-C.
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objeCtives: Total Parenteral Nutrition (TPN) is an essential pharmaceutical prepa-
ration used in hospitalized patients to whom enteral feeding is not possible or 
for critical care patients with compromised gastrointestinal tract function. Use of 
TPN reduce the incidence of malnutrition, which is a leading complication associ-
ated with various medical and surgical conditions. Hence the purpose of the study 
is to assess TPN utilization in surgical in-patients and its outcomes. Methods: 
Retrospective analysis of surgical in-patients receiving TPN from Jan 2011 to Dec 
2012 in a tertiary care hospital was carried out. Patients who were administered 
TPN were included in the study. Patient characteristics and treatment details were 
collected. Data were analyzed using SPSS ® version 20.0. Results: A total of 120 
patients were enrolled in the study. The mean age of patients taking TPN was 
48.9±17.7 years. Majority of patients (67.5%) were males. A large proportion (40.8%) 
of the patients receiving TPN were those w underwent surgical procedures and 
had intestinal obstruction. Major metabolic complication included hypernatremia 
(26.5%) followed by hyperglycemia. Higher (79.5%) recovery rate was observed in 
patients who received TPN peripherally compared to those who received it via a 
central line. Among the patients receiving TNP, mortality was higher in patients 
with infections (31.9%) than without infection. In 93.3% of the cases, TPN starts 
were considered to be appropriate indications and rest inappropriate. From an eco-
